Joint Research on a Novel HSP105-Related Cancer Immunotherapy
First written in FY2020-Q1. 5 of 7 entries say "Advanced", first in FY2020-Q3. Latest entry: 2026-05-27.
No other company in this theme has enough history to compare yet.
- 2026-05-27AdvancedPresentation materials on financial results
「Continuing a mouse efficacy study with the aim of obtaining nonclinical proof-of-concept data for HSP-105-specific TCR-T cells」
For HSP-105-related research, the company is continuing mouse efficacy studies with the aim of obtaining nonclinical proof-of-concept data. - FY2025AdvancedAnnual report
「As a result of the joint research to date, the company successfully produced TCR-T cells into which an HSP105-specific TCR gene had been introduced and confirmed that they exhibited cytotoxic activity against HSP105-expressing cancer cells. The company is currently proceeding with efficacy studies in a mouse solid-tumor model.」
The HSP105-related research progressed to successful production of TCR-T cells and confirmation of cytotoxic activity against HSP105-expressing cancer cells, and is currently at the stage of confirming efficacy in a mouse solid-tumor model. - FY2023RestatedAnnual report
「Under the joint research agreement entered into with the National Cancer Center in October 2019 for the practical application of a novel cancer immunotherapy related to Heat Shock Protein 105 (HSP105), one of the cancer antigen proteins, the company has dispatched researchers to the National Cancer Center and is advancing the joint research.」
The company continues to advance the HSP105-related joint research, including the dispatch of researchers. - FY2023-Q2AdvancedAnnual report
「The development of the manufacturing process for the target immune cells and other issues in developing a novel cancer immunotherapy related to the cancer antigen protein HSP105 had required time to resolve, but the company is extending the planned expenditure period because progress has been made toward resolving these issues.」
For the HSP105-related cancer immunotherapy, the company stated that progress had been made toward resolving issues including development of the immune-cell manufacturing process, while the planned expenditure period for research expenses was extended. - FY2022AdvancedAnnual report
「Under the joint research agreement entered into with the National Cancer Center in October 2019 for the practical application of a novel cancer immunotherapy related to Heat Shock Protein 105 (HSP105), one of the cancer antigen proteins, the company has dispatched researchers to the National Cancer Center and is advancing the joint research.」
For the HSP105-related joint research, the company described an implementation structure for advancing the research, including the dispatch of researchers to the National Cancer Center. - FY2020-Q3AdvancedAnnual report
「Expenses related to the research and development of HSP105 in a joint research project with the National Cancer Center」
For HSP105-related research, research and development expenses were specified as a use of proceeds for the 16th Stock Acquisition Rights. - FY2020-Q1First statedAnnual report
「In the same month, we entered into a joint research agreement with the National Cancer Center to commercialize a novel cancer immunotherapy relating to Heat Shock Protein 105 (HSP105), one of the cancer antigen proteins.」
The Company signed a joint research agreement with the National Cancer Center to commercialize a novel cancer immunotherapy relating to HSP105.